What is a stock summary page? Click here for an overview.
Business Description
Keymed Biosciences Inc
ISIN : KYG5252B1023
Compare
Compare
Traded in other countries / regions
02162.Hong Kong64Z.Germany Index Membership
Hong Kong Stock Connect IPO Date
2021-07-08Description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.56 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | -1.14 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.81 | |||||
| Beneish M-Score | 0.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 31 | |||||
| 3-Year EPS without NRI Growth Rate | 25.2 | |||||
| 3-Year FCF Growth Rate | -67.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 59.1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.12 | |||||
| 9-Day RSI | 43.51 | |||||
| 14-Day RSI | 49.16 | |||||
| 3-1 Month Momentum % | -12.93 | |||||
| 6-1 Month Momentum % | -16.98 | |||||
| 12-1 Month Momentum % | -17.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.98 | |||||
| Quick Ratio | 4.83 | |||||
| Cash Ratio | 4.6 | |||||
| Days Inventory | 1045.21 | |||||
| Days Sales Outstanding | 51.67 | |||||
| Days Payable | 443.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.7 | |||||
| Shareholder Yield % | -3.24 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.39 | |||||
| Operating Margin % | -972.56 | |||||
| Net Margin % | -913.17 | |||||
| FCF Margin % | -1106.04 | |||||
| ROE % | -24.71 | |||||
| ROA % | -18.92 | |||||
| ROIC % | -68.92 | |||||
| 3-Year ROIIC % | -32.65 | |||||
| ROC (Joel Greenblatt) % | -77.14 | |||||
| ROCE % | -20.18 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 104.4 | |||||
| PB Ratio | 3.45 | |||||
| Price-to-Tangible-Book | 3.46 | |||||
| EV-to-EBIT | -9.71 | |||||
| EV-to-EBITDA | -11.08 | |||||
| EV-to-Revenue | 85.71 | |||||
| EV-to-FCF | -8.38 | |||||
| Price-to-Net-Current-Asset-Value | 5.61 | |||||
| Price-to-Net-Cash | 6.47 | |||||
| Earnings Yield (Greenblatt) % | -10.3 | |||||
| FCF Yield % | -9.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Keymed Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 88.368 | ||
| EPS (TTM) (HK$) | -3.084 | ||
| Beta | 0.78 | ||
| 3-Year Sharpe Ratio | 0.34 | ||
| 3-Year Sortino Ratio | 0.54 | ||
| Volatility % | 38.22 | ||
| 14-Day RSI | 49.16 | ||
| 14-Day ATR (HK$) | 2.051187 | ||
| 20-Day SMA (HK$) | 35.455 | ||
| 12-1 Month Momentum % | -17.91 | ||
| 52-Week Range (HK$) | 26.6 - 47.5 | ||
| Shares Outstanding (Mil) | 277.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Keymed Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Keymed Biosciences Inc Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Keymed Biosciences Inc Frequently Asked Questions
What is Keymed Biosciences Inc(HKSE:02162)'s stock price today?
The current price of HKSE:02162 is HK$35.30. The 52 week high of HKSE:02162 is HK$47.50 and 52 week low is HK$26.60.
When is next earnings date of Keymed Biosciences Inc(HKSE:02162)?
The next earnings date of Keymed Biosciences Inc(HKSE:02162) is .
Does Keymed Biosciences Inc(HKSE:02162) pay dividends? If so, how much?
Keymed Biosciences Inc(HKSE:02162) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers